Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Advances in Neurobiology|March 17, 2023
Reverse Engineering Drugs: Lorcaserin as an ExampleTiffany Schwasinger-Schmidt, Sheldon H Preskorn
Advances in Neurobiology|March 17, 2023
Discovery of New Transmitter Systems and Hence New Drug TargetsTiffany Schwasinger-Schmidt, Sheldon H Preskorn
Langenbeck'S Archives of Surgery|July 21, 2023
Prevalence of elevated alkaline phosphatase levels among post-bariatric surgery patientsClaudius Ciecko, Hayrettin Okut, Brent Lancaster, et al.
Kansas Journal of Medicine|September 20, 2021
Bariatric Metabolic Surgery Reduced Liver Enzyme Levels in Patients with Non-Alcohol Fatty Liver DiseaseKennedy Kirkpatrick, Bobbie Paull-Forney, Hayrettin Okut, et al.
Pharmacological Research|July 30, 2013
Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF ratsTiffany Schwasinger-Schmidt, David C Robbins, S Janette Williams, et al.
Journal of Alzheimer'S Disease : JAD|August 29, 2022
Acceptability and Preliminary Effectiveness of a Remote Dementia Educational Training Among Primary Care Providers and Health NavigatorsJaime Perales-Puchalt, Ryan Townley, Michelle Niedens, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 21, 2024
A service-oriented approach to clinical trial recruitment for dementia and brain health: Methods and case examples of MyAlliance for Brain HealthEric D Vidoni, Emma Swinford, Kelli Barton, et al.
Muscle & Nerve|November 8, 2024
A 40-week phase 2B randomized, multicenter, double-blind, placebo-controlled study evaluating the safety and efficacy of memantine in amyotrophic lateral sclerosisSalman Bhai, Todd Levine, Dan Moore, et al.
JAMA|November 17, 2023
Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical TrialThomas G Stewart, Paulina A Rebolledo, Ahmad Mourad, et al.
Medrxiv : the Preprint Server for Health Sciences|May 27, 2024
Effect of Montelukast vs Placebo on Time to Sustained Recovery in Outpatients with COVID-19: The ACTIV-6 Randomized Clinical TrialRussell L Rothman, Thomas G Stewart, Ahmad Mourad, et al.
Pageof 2